The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation.
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Merck; Novartis; Roche/Genentech
Consulting or Advisory Role - Agenus; AstraZeneca; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca
 
Jacob Stephen Thomas
Travel, Accommodations, Expenses - eFFECTOR Therapeutics; Pfizer
 
Diana L. Hanna
Consulting or Advisory Role - Boehringer Ingelheim
 
Lillian L. Siu
Leadership - Agios (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Loxo; Merck; MorphoSys; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Symphony Evolution (Inst)
 
Nilofer Saba Azad
Honoraria - AMAG Pharmaceuticals
Consulting or Advisory Role - AMAG Pharmaceuticals; Dava Oncology
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Intensity Therapeutics; Merck (Inst); Syndax (Inst)
 
Giles Francis Whalen
No Relationships to Disclose
 
Lewis H. Bender
Employment - Intensity Therapeutics
Leadership - Intensity Therapeutics
Stock and Other Ownership Interests - Intensity Therapeutics
 
Ian B. Walters
Employment - Intensity Therapeutics; Portage Biotech; Saugatuck Therapeutics; Slate Pharmaceuticals; Slate Pharmaceuticals
Leadership - Intensity Therapeutics; Portage Biotech; Portage Biotech; Saugatuck Therapeutics; Slate Pharmaceuticals; Slate Pharmaceuticals
Stock and Other Ownership Interests - Intensity Therapeutics; Portage Biotech; Slate Pharmaceuticals; Slate Pharmaceuticals
Consulting or Advisory Role - Mina Therapeutics
 
Anthony J. Olszanski
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; G1 Therapeutics; Merck; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Immunocore (Inst); Incyte (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Targovax (Inst)
Travel, Accommodations, Expenses - Takeda